Immunising against meningococcal serogroup Y using proteins
The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W135 and Y.
1. A method of inducing an immune response in a subject against serogroup Y of Neisseria meningitidis , comprising administering to the subject an immunologically effective amount of a composition comprising an aluminum adjuvant and a purified immunogenic Neisseria meningitidis serogroup B 741 protein having at least 95% sequence identity to the sequence of SEQ ID NO: 10, a purified immunogenic Neisseria meningitidis serogroup B NadA protein having at least 95% sequence identity to the sequence of SEQ ID NO: 2, a purified immunogenic Neisseria meningitidis serogroup B 287 protein having at least 95% sequence identity to the sequence of SEQ ID NO: 6, a purified immunogenic Neisseria meningitidis serogroup B 936 protein having at least 95% sequence identity to the sequence of SEQ ID NO: 4, and a purified immunogenic Neisseria meningitidis serogroup B 953 protein having at least 95% sequence identity to the sequence of SEQ ID NO: 5.
2. The method of claim 1 , wherein an immune response against serogroup A, B, C and/or W135 of N. meningitidis is also induced in the subject.
3. The method of claim 1 , wherein the composition further comprises a histidine buffer.
4. The method of claim 1 , wherein the aluminum adjuvant comprises an aluminum phosphate.
5. The method of claim 3 , wherein the aluminum phosphate is aluminum hydroxyphosphate.
6. The method of claim 4 , wherein the composition further comprises a histidine buffer.
7. The method of claim 3 , wherein the aluminum adjuvant is amorphous.
8. The method of claim 7 , wherein the aluminum phosphate is aluminum hydroxyphosphate.
9. The method of claim 8 , wherein the composition further comprises a histidine buffer.
10. The method of claim 1 , wherein the composition further comprises sodium chloride at a concentration of 8-12 mg/ml.
11. The method of claim 10 , wherein the aluminum adjuvant comprises an aluminum phosphate.
12. The method of claim 11 , wherein the aluminum phosphate is aluminum hydroxyphosphate.
13. The method of claim 12 , wherein the composition further comprises a histidine buffer.
14. The method of claim 13 , wherein the composition further comprises polysorbate 80 wherein the concentration of polysorbate 80 is less than 0.01 percent.
15. The method of claim 1 , wherein the composition further comprises an outer membrane vesicle preparation.